Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

A dose-escalation and dose-expansion study of MEDI4736 (a monoclonal antibody that targets
programmed cell death-1 ligand 1 [PD-L1]) to evaluate the safety, tolerability, PK, IM, and
antitumor activity of MEDI4736 as monotherapy or in combination with Tremelimumab with or
without Azacitidine in adult patients with myelodysplastic syndrome.

Inclusion Criteria:

Adult male or female subjects with pathologically confirmed MDS who failed to respond,
relapsed after an initial response, or were unable to tolerate hypomethylating agents, ECOG
performance status of 0 - 2, and adequate organ and marrow function.

Exclusion Criteria:

Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment,
prior MAb against CTLA-4, PD-1, or PD-L1, alllogenic or haploidentical transplant, current
immunosuppressive medication or autoimmune or inflammatory disease.